治疗活动性银屑病关节炎新药阿普斯特

Apremilast: a New Drug for the Treatment of Psoriatic Arthritis

银屑病性关节炎(PSA)是一种致残性慢性疾病,需长期治疗。目前的治疗方法不少,但因不良反应较严重、疗效不佳、价格昂贵、耐受性差等因素,至今仍无满意治疗方法,因此需要一种更安全、有效、耐受性好的治疗药物。阿普斯特(apremilast)是一种新型的口服小分子磷酸二酯酶4(PDE4)抑制药,通过剂量依赖性抑制人类滑膜细胞释放肿瘤坏死因子(TNF)-α而发挥作用,临床试验表明该药可有效治疗银屑病关节炎,改善体征和症状,最常见不良反应为腹泻、恶心、头痛,大多数为轻度或中度。

Psoriatic arthritis is a chronic disabling disease which needs long-term treatment. There are lots of drugs for the treat- ment of the disease now, however, most of them have severe adverse reactions with poor efficacy, high price and intolerance, so up till now, there is no satisfied treatment used in clinics. Apremilast is a new PDE4 inhibitor with low molecular weight, which can be with oral administration. It inhibits human synovial cells releasing TNF-a in a does-dependent manner. Clinical studies have shown that Apremilast can treat psoriatic arthritis effectively with the improvement of signs and symptoms. Its main adverse reactions include diarrhea. nausea and headache, and most of them are mild or moderate.